目的评价奥利司他治疗非酒精性脂肪性肝病的效果。方法从PubMed、Web of Science、中国知网、中国生物医学文献数据库、维普数据库和万方数据知识服务平台数据库检索从建库开始至2023年9月国内外关于奥利司他治疗非酒精性脂肪性肝病的...目的评价奥利司他治疗非酒精性脂肪性肝病的效果。方法从PubMed、Web of Science、中国知网、中国生物医学文献数据库、维普数据库和万方数据知识服务平台数据库检索从建库开始至2023年9月国内外关于奥利司他治疗非酒精性脂肪性肝病的文献。运用Review Manager 5.4.1进行Meta分析。结果研究共纳入8篇文献,共450例患者,纳入研究无发表偏倚。Meta分析结果显示,研究组患者为丙氨酸转氨酶(ALT)[MD=-35.18,95%CI(-56.71,-13.64),P<0.01],天冬氨酸转氨酶(AST)(MD=-25.69,95%CI(-43.13,-8.26),P<0.01],谷氨酰转移酶(GGT)[MD=-48.12,95%CI(-74.65,-21.60),P<0.01],总胆固醇[MD=-2.13,95%CI(-4.06,-0.21),P=0.03],三酰甘油[MD=-2.20,95%CI(-4.21,-0.19),P=0.03]水平低于对照组,差异均具有统计学意义。结论奥利司他治疗非酒精性脂肪性肝病可有效降低患者ALT、AST、GGT、总胆固醇及三酰甘油水平。展开更多
In order to further improve the transfection efficiency of hydroxyapatite nanoparticle （HAp）, arginine functionalized hydroxyapatite （HAp/Arg） was synthesized by hydrothermal synthesis. The morphology, crystallite...In order to further improve the transfection efficiency of hydroxyapatite nanoparticle （HAp）, arginine functionalized hydroxyapatite （HAp/Arg） was synthesized by hydrothermal synthesis. The morphology, crystallite size and zeta potential of the HAp/Arg were characterized by transmission electron microscopy （TEM）, atomic force microscopy （AFM） and zeta potential analyzer. The loading and protecting properties of HAp/Arg to DNA were tested by electrophoresis. Its cytotoxicity was also measured in Hela cells and HAEC cells by MTT and LDH, and its transfection efficiency was examined by fluorescence microscope and flow cytometry. The results reveal that HAp/Arg is short rod-like and nano single crystal, the mean diameter is 50-90 nm and zeta potential is 35.8 mV at pH 7.4. HAp/Arg to DNA can be condensed by electrostatic effect and protect DNA against degradation in DNase I, and shows high transfection efficiency without cytotoxicity. These results suggest that HAp/Arg can be a promising alternative as a novel gene delivery system.展开更多
文摘目的评价奥利司他治疗非酒精性脂肪性肝病的效果。方法从PubMed、Web of Science、中国知网、中国生物医学文献数据库、维普数据库和万方数据知识服务平台数据库检索从建库开始至2023年9月国内外关于奥利司他治疗非酒精性脂肪性肝病的文献。运用Review Manager 5.4.1进行Meta分析。结果研究共纳入8篇文献,共450例患者,纳入研究无发表偏倚。Meta分析结果显示,研究组患者为丙氨酸转氨酶(ALT)[MD=-35.18,95%CI(-56.71,-13.64),P<0.01],天冬氨酸转氨酶(AST)(MD=-25.69,95%CI(-43.13,-8.26),P<0.01],谷氨酰转移酶(GGT)[MD=-48.12,95%CI(-74.65,-21.60),P<0.01],总胆固醇[MD=-2.13,95%CI(-4.06,-0.21),P=0.03],三酰甘油[MD=-2.20,95%CI(-4.21,-0.19),P=0.03]水平低于对照组,差异均具有统计学意义。结论奥利司他治疗非酒精性脂肪性肝病可有效降低患者ALT、AST、GGT、总胆固醇及三酰甘油水平。
基金Project(2013SK2024)supported by the Key Projects in Social Development Pillar Program of Hunan Province,ChinaProject(20130162120094)supported by Specialized Research Fund for the Doctoral Program of Higher Education(SRFDP),Ministry of Education,ChinaProjects(81071869,51305464)supported by the National Natural Science Foundation of China
文摘In order to further improve the transfection efficiency of hydroxyapatite nanoparticle （HAp）, arginine functionalized hydroxyapatite （HAp/Arg） was synthesized by hydrothermal synthesis. The morphology, crystallite size and zeta potential of the HAp/Arg were characterized by transmission electron microscopy （TEM）, atomic force microscopy （AFM） and zeta potential analyzer. The loading and protecting properties of HAp/Arg to DNA were tested by electrophoresis. Its cytotoxicity was also measured in Hela cells and HAEC cells by MTT and LDH, and its transfection efficiency was examined by fluorescence microscope and flow cytometry. The results reveal that HAp/Arg is short rod-like and nano single crystal, the mean diameter is 50-90 nm and zeta potential is 35.8 mV at pH 7.4. HAp/Arg to DNA can be condensed by electrostatic effect and protect DNA against degradation in DNase I, and shows high transfection efficiency without cytotoxicity. These results suggest that HAp/Arg can be a promising alternative as a novel gene delivery system.
